"We want the best for all cancer patients. The role of the Cancer Drugs Fund is to fund medicines that have been rejected or not approved by NICE in order to ensure that NHS patients have improved access, as they do in other EU countries. We share the desire of the Public Accounts Committee to achieve a sustainable, affordable solution that provides rapid access to new medicines for NHS patients."
Dr Paul Catchpole, Director - Value and Access, said in response to the Public Accounts Committee report, published today. He continued;
"At the moment too many patients miss out on access to new treatments. As the consultation on the way forward for the Cancer Drugs Fund comes to an end, we urge Government to seize the opportunity and transform the way cancer drugs are assessed by NICE to achieve a sustainable, affordable solution that provides rapid access to new medicines for NHS patients.
"Medicines bring huge benefits to patients and are one of the most scrutinised elements of NHS spending. In addition a nationally negotiated pricing scheme limits growth in the medicines bill at a time of increasing demand from an ageing population and the rising challenges of chronic conditions. Under this scheme the pharmaceutical industry will be contributing around £3bn over five years to support the NHS at this time of austerity."